The pharma industry briefing
The latest news, approvals and clinical trials you need to know about this month
The amount granted by the UK Government to tackle antimicrobial resistance
The expected CAGR of the peanut allergy market, which is forecast to reach $4.5bn by 2027
The amount that the immunology drugs market is projected to reach by 2023
The number of healthcare firms listed in the PwC’s top 100 global companies
The amount that Sanofi has invested in developing a new R&D hub in Chengdu, China
China pushes for lower cancer drug prices: Xinhua
China’s new medical insurance regulator will begin negotiations with domestic and overseas pharmaceutical companies to lower prices of cancer drugs in a bid to cut the financial burden on patients.
Indivior's shares soar
Indivior’s shares jumped more than 33% after a US court blocked a rival from selling a cheaper copycat of the British drugmaker’s bestselling opioid addiction treatment.
Genetically modified babies given go ahead by UK ethics body
The creation of babies whose DNA has been altered to give them what parents perceive to be the best chances in life has received a cautious green light in a landmark report from a leading UK ethics body.
Source: The Guardian
Drugs that kill off old cells may limit a body’s aging
A new study, conducted using mice, indicates that having a small population of cells that have hit the wall due to aging can induce symptoms of age-related decline in otherwise young mice. And a drug combination that targets these cells can block these problems from taking root. The same drugs, when given to elderly mice, also reduce mortality and limit some of the symptoms of age.
Source: Ars Technica
FDA approves the first drug with an indication for treatment of smallpox
The US Food and Drug Administration has approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox.
Prostate drug approved for use in non-metastatic cases
The US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic prostate cancer.
EC approves expanded indication for Sprycel
Bristol-Myers Squibb has secured approval from the European Commission for the use of its Sprycel (dasatinib) to treat Philadelphia chromosome-positive chronic myeloid leukaemia.
Source: The Pharma Letter
FDA approves drug for excessive drooling
The US Food and Drug Administration has approved Merz North America’s supplemental biologics license application for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, otherwise known as excessive drooling.
Source: The Pharma Times
Share this article